AstraZeneca is leaving no stone unturned in its effort to make baxdrostat the first aldosterone synthase inhibitor (ASI) to get approval for hard-to-treat hypertension. The FDA has now started a ...
Medscape UK : Get the latest medical news, drug alerts, expert commentary, clinical guidelines, and practice of medicine coverage for UK healthcare professionals.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results